Canbridge Pharmaceuticals Receives Marketing Approval in Taiwan for Puma's Nerlynx

Aug 07, 2020

|

NEW YORK – Canbridge Pharmaceuticals said on Thursday that it received approval from the Taiwan Food and Drug Administration to market neratinib (Puma Biotechnology's Nerlynx) as an extended adjuvant treatment for adult patients with early-stage, HER2-positive breast cancer after treatment with trastuzumab (Genentech's Herceptin).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Canbridge Pharmaceuticals Receives Marketing Approval in Taiwan for Puma's Nerlynx

To read the full story....

Breaking News

CAR T-Cell Therapy Shows Signs of Anti-Tumor Activity in Pediatric Neuroblastoma Patients

Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy

PMV Pharma Begins Trial of Investigational Drug in p53-Mutated Cancers

Persephone Biosciences Launches Study to Assess Microbiome's Role in Cancer Treatment Response

Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

Featured White Papers

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

What's Popular?

Genetic Testing Challenges in Oncology: BRCA2-Positive Healthy Young Man Recommended Mastectomy

Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care

CAR T-Cell Therapy Shows Signs of Anti-Tumor Activity in Pediatric Neuroblastoma Patients

SEngine Precision Medicine IDs Potential Ovarian Cancer Treatment Combos Using Organoid Approach

FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

Sponsorships